Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 2014, 184278
eCollection

Study on the Therapeutic Benefit on Lactoferrin in Patients With Colorectal Cancer Receiving Chemotherapy

Affiliations

Study on the Therapeutic Benefit on Lactoferrin in Patients With Colorectal Cancer Receiving Chemotherapy

Tarek M Moastafa et al. Int Sch Res Notices.

Abstract

A double-blinded parallel randomized controlled clinical trial was conducted on two groups of colorectal cancer patients to study the therapeutic benefit of orally administered bovine lactoferrin (bLF) on colorectal cancer patients having age ranges from 20 to 71 years and who received 5-fluorouracil and leucovorin calcium. Test group (15 patients) received oral bLF 250 mg/day beside chemotherapy for three months. Control group (15 patients) received chemotherapy only. Serum lactoferrin (LF), serum glutathione-s-transferase enzyme (GST), interferon gamma (INF-γ), tumor marker carcinoembryonic antigen (CEA), renal function tests, hepatic function tests, and complete blood count were measured for both groups before and at the end of the trial. Although, there was a significant effect of oral bLF (250 mg/day) that indicated a significant improvement in mean percent of change of all parameters 3 months after treatment, there was no significant difference between results of patients in the test group and patients in the control group after treatment. This result suggests that oral bLF has significant therapeutic effect on colorectal cancer patients. Our study suggests that daily administration of bLF showed a clinically beneficial effect to colorectal cancer patients with better disease prognosis but that needs further looking into.

Figures

Figure 1
Figure 1
Mean serum lactoferrin (LF) and serum glutathione-s-transferase (GST) among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).
Figure 2
Figure 2
Mean interferon gamma (INF-γ) among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).
Figure 3
Figure 3
Mean values of RBCs and WBCs findings among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).
Figure 4
Figure 4
Mean carcinoembryonic antigen (CEA) and as a tumor marker among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).
Figure 5
Figure 5
Mean blood urea nitrogen (BUN) and serum creatinine among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).
Figure 6
Figure 6
Mean aspartate aminotransferase (AST) and alanine aminotransferase (ALT) among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).

Similar articles

See all similar articles

Cited by 2 articles

References

    1. Picere A., Legrand D., Mazurier J. Lactoferrin, a multifunctional protein. Médecine Sciences. 2009;25(4):361–369. doi: 10.1051/medsci/2009254361. - DOI - PubMed
    1. Latorre D., Puddu P., Valenti P., Gessani S. Reciprocal interactions between lactoferrin and bacterial endotoxins and their role in the regulation of the immune response. Toxins. 2010;2(1):54–68. doi: 10.3390/toxins2010054. - DOI - PMC - PubMed
    1. Berlutti F., Pantanella F., Natalizi T., et al. Antiviral properties of lactoferrin—a natural immunity molecule. Molecules. 2011;16(8):6992–7018. doi: 10.3390/molecules16086992. - DOI - PMC - PubMed
    1. Bharadwaj S., Naidu A. G. T., Betageri G. V., Prasadarao N. V., Naidu A. S. Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women. Osteoporosis International. 2009;20(9):1603–1611. doi: 10.1007/s00198-009-0839-8. - DOI - PubMed
    1. Marian E. D. S., Mireya D. L. G., Rafael C. R. Lactoferrin as an Adjunctive Agent in the Treatment of Bacterial Infections Associated with Diabetic Foot Ulcers, Global Perspective on Diabetic Foot Ulcerations. InTech; 2011.

LinkOut - more resources

Feedback